Roche's Q1 pipeline cleanup claims PhII myelofibrosis drug, early-stage MAGE-A4 work
More than three years after Roche put down $390 million in cash to buy the biotech Promedior, the anti-fibrotic drug at the center of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
